CurrentBlue Cross Blue Shield - TennesseePolicy N/A

Prescription Medication and Illicit Drug Testing in the Outpatient Setting

Coverage and reimbursement criteria for presumptive and definitive outpatient drug testing (primarily urine and oral fluid) for prescription and illicit substances; applies to providers submitting claims to Blue Cross Blue Shield - Tennessee.

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyPrescription Medication and Illicit Drug Testing in the Outpatient Setting

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionRequest definitive testing (up to seven drug classes) only when specifically ordered by the treating physician with documented clinical rationale.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

up to 7drug classes allowed for definitive testing

1-4/yrpresumptive monitoring frequency tiers

1-3/modefinitive testing frequency (31–90 days)

5common DOA panel components

Multipleprocedure codes listed

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria and Indications

Presumptive Screening — Covered Indications

Presumptive drug screening (qualitative, semi-quantitative, quantitative) MEETS COVERAGE CRITERIA when ANY of the following are met

Presumptive screening covered indications: a) Evaluation of individuals treated for chronic non-cancer pain when clinical evaluation (history/signs/symptoms) suggests use of nonprescribed medications or illicit substances, including prior to initiating chronic opioid therapy and for routine monitoring. b) Pregnant individuals at high risk for substance abuse when suspicion exists based on screening answers or PDMP data. c) Newborns with a history of maternal substance abuse or when the birthing parent has altered/agitated mental status. d) Candidates for organ transplant with a history of substance abuse to demonstrate abstinence prior to transplant. e) Individuals with suspicion of or diagnosis of mental illness where substance use may affect diagnosis or treatment. f) Individuals with attention-deficit/hyperactivity disorder or disruptive behavior disorders. g) Cancer patients receiving opioid pain medication. h) Individuals with epilepsy when toxin/drug exposure may alter management. i) Management and compliance monitoring of individuals in substance abuse treatment or dependence (random qualitative testing per documented frequency after baseline). j) When substance abuse is in the differential diagnosis of the presenting condition.

Monitoring frequencies and definitive testing rules are specified in related criteria

Monitoring Frequency Rules

Monitoring frequency rules for presumptive and definitive testing

Presumptive monitoring frequency for chronic opioid therapy: Monitoring frequency tied to risk assessment: low-risk patients — up to 1–2 times per year after initiation; moderate-risk patients — up to 2–4 times per year after initiation; high-risk patients — up to 4–5 times per year after initiation; individuals with aberrant behavior — testing at time of visit (random testing covered).

Per policy risk-tier definitions and examples

Definitive testing frequency for substance use disorder patients: For patients in substance abuse treatment: 0–90 consecutive days abstinence — random definitive testing up to 1–2 times per week; 31–90 consecutive days — random definitive testing 1–3 times per month (no more than 3 in a month); >90 consecutive days — definitive testing 1–3 times every three months (no more than 3 in a 3-month period).frequency limits as stated

Definitive testing panels limited to ≤7 drug classes

Definitive Testing — Covered and Not Covered

Definitive/confirmatory testing coverage rules

When definitive testing meets criteria: Laboratory-based definitive qualitative or quantitative testing (up to seven drug classes) MEETS COVERAGE CRITERIA when specifically requested with documented rationale by the treating physician and any of the following apply: a) presumptive screen result is inconsistent with the medical history, clinical presentation, or patient report; b) accurate and reliable results are necessary for diagnosis or treatment decisions in substance use disorder or dependence; c) monitoring individuals on opioid therapy to assess adherence and detect non-prescribed opioids; d) no suitable presumptive test exists or the presumptive assay does not adequately detect the specific drug/metabolite; e) to definitively identify specific drugs within a large drug family; f) when a definitive concentration is needed to guide clinical management.≤7 drug classes

Panels >7 classes and proprietary tests are not covered

Definitive testing not covered conditions: Confirmatory/definitive testing for panels larger than seven drug classes DOES NOT MEET COVERAGE CRITERIA. Definitive or presumptive testing using proprietary tests (e.g., CareView360) DOES NOT MEET COVERAGE CRITERIA. Any AMA definitive drug class codes are not reimbursed.

See coding and not-covered sections

Specimen and Method Limitations

Specimen and test method coverage limitations

Specimen types covered: Coverage is limited to urine or oral fluid specimens; blood specimens are covered only for patients with anuric chronic renal failure (e.g., dialysis patients where blood must be collected pre-dialysis).

Same-day duplicate testing of the same analyte from two different specimens is not reimbursed

Specimen validity testing (e.g., urine specific gravity, urine creatinine, pH, urine oxidant level, genetic identity testing) DOES NOT MEET COVERAGE CRITERIA and is not reimbursed.

Proprietary validity assays also excluded

Medically Indicated Uses

Covered when testing is medically indicated in the following contexts:

Covered clinical contexts: Drug treatment programs; pain management monitoring (baseline and random monitoring to assess compliance and detect non-prescribed use); psychiatric evaluation when stimulant or other toxic exposure is suspected; acute presentations where drug exposure would alter management (e.g., suspected overdose, altered mental status); pre-admission or baseline testing for opioid treatment programs; testing in patients with seizure disorders where drug interactions (e.g., cocaine) may affect therapy; and targeted testing when substance abuse is in the differential diagnosis.

Supported by cited studies and guidelines

Recommended Testing Workflow

Preferred testing approach when monitoring drug therapy or confirming initial positive screens:

Screen-confirmation workflow: Initial testing may be performed with presumptive immunoassays (POC or laboratory-based) for rapid assessment, with reflex to definitive MS-based confirmatory testing (GC‑MS, LC‑MS/MS) for positive, unexpected, or clinically discordant results; definitive methods are preferred for baseline assessment and when results will inform significant clinical decisions.

Clinicians must consult package inserts or laboratory personnel to understand assay limitations

Interpretation Caveats

Considerations and limitations that affect interpretation and coverage decisions:

Assay limitations: Immunoassays (including POC) have lower sensitivity and specificity than definitive MS-based tests and are susceptible to false-positives and false-negatives (examples: benzodiazepine immunoassays may miss certain agents; one study reported a 28% false-negative rate for benzodiazepines); cross-reactivity and assay cutoff differences can affect results and interpretation. Clinicians should reference assay package inserts or consult the laboratory when interpreting results.

Incorrect interpretation without lab consultation may lead to inappropriate management

Medically necessary testing for baseline and monitoring

Covered when testing is used as baseline or ongoing monitoring for patients prescribed controlled substances or when clinically indicated to alter medical management

Baseline and monitoring: Perform baseline urine drug monitoring prior to initiation of acute or chronic controlled substance therapy. Ongoing monitoring frequency should be determined by patient risk: low-risk — at least annually; moderate-risk — two or more times per year; high-risk — three or more times per year. Additional monitoring may be performed as clinically necessary.risk-tier frequencies

Guideline-based recommendations (Argoff et al., AACC) support this approach

Test modality preference: Definitive testing (GC‑MS, LC‑MS/MS) is recommended as the most accurate method for baseline assessment and most monitoring; laboratory immunoassays or POC immunoassays may be acceptable for low-risk patients or when required by payer/institutional policies but positive or discordant immunoassay results should be confirmed by definitive testing.

Strength of recommendation: A for definitive testing

Alternate matrices:

Coverage Criteria for UDT and Confirmatory Testing

Covered when testing is clinically indicated according to risk stratification and guideline recommendations:

Preferred test selection: Use qualitative definitive testing preferentially over immunoassays when available because of superior sensitivity and specificity; definitive testing should be used whenever results will inform major clinical or nonclinical decisions.

Supported by multiple society recommendations

When to use presumptive immunoassay: POC or laboratory-based presumptive immunoassays may be used for initial screening, baseline assessment, or routine monitoring provided clinicians understand assay limitations and document rationale; random testing is recommended for monitoring in pain management populations.

Strength of Recommendation: B for immunoassays

Confirmatory testing triggers: Obtain definitive confirmatory testing for any presumptive immunoassay result that is inconsistent with clinical expectations, unexplained, or when legal/clinical implications are substantial.

Strength of Recommendation: A

Monitoring Frequency by Risk

Testing frequency recommendations (use risk stratification to determine number of tests):

Low risk: Consider annual to semiannual testing for low-risk patients; some guidance cites 1 test per year as acceptable for low-risk individuals.1-4 per year

Range varies by guideline

Moderate risk: Recommend approximately 2–4 tests per year for moderate-risk patients (guideline-dependent).2-4 per year

Follow local guideline selection

High risk: Recommend more frequent testing for high-risk patients — up to monthly or at each visit/refill for highest-risk individuals; random/unannounced testing preferred.Up to monthly

Covered indications and contexts

Covered when supported by clinical indication as reflected in guidelines from specialty and federal sources

UDT for opioid therapy: Use urine drug testing as part of risk assessment prior to initiation of opioid therapy and for ongoing monitoring of patients on long-term opioids; testing should be integrated with clinical judgment and documented risk mitigation strategies.clinical judgment

PMFT, VA/DoD, and other specialty guidance support UDT use

Testing in acute neurologic presentations: Consider toxicology testing in children with status epilepticus or adults when etiology is unexplained to detect possible substance exposure that would alter management.when no apparent etiology

AAN guidance

Psychiatric evaluation: Toxicology screening is indicated for acute onset or exacerbations of psychosis when substance exposure cannot be ruled out and results would change management.

Coding-led coverage guidance

Coverage and reimbursement guidance based on coding and applicable government policy

Policy determination: Claims must report the specific CPT/HCPCS/U-code that corresponds to the performed presumptive or definitive testing method and panel size; definitive testing panels are limited by policy to seven drug classes for coverage purposes (use G‑codes per panel size where applicable).

Procedure codes map to test methodology and panel size

Regulatory precedence: If there is a conflict between this Policy and an applicable government policy (LCD/NCD or state Medicaid), the government policy controls coverage determinations for the affected member.

See Applicable State and Federal Regulations

LDT regulation: Laboratory-developed tests (LDTs) are regulated as high-complexity under CLIA '88; while commonly used, LDTs are not FDA-cleared and labs must follow CLIA requirements when using these assays.

FDA/CLIA guidance referenced

This policy does not apply to state or federally mandated, forensic, or legally required drug testing (for example, court‑ordered screens), employment‑related testing (including commercial driver licensing or pre‑employment screens), testing performed as part of routine physical/medical examinations, testing rendered in urgent or emergency care, or as a routine component of behavioral health assessments. Applicability of coverage in these settings is determined by the member's specific benefits and by any applicable government regulations referenced elsewhere in this policy.

Proprietary laboratory assays and manufacturer‑specific panels are excluded when they are described as proprietary tests (for example, CareView360 and similar U‑code panels) and are not covered. In addition, laboratory definitive panels that include more than 7 drug classes do not meet coverage criteria and will be denied. Claims for proprietary multi‑analyte panels should be billed only with appropriate codes and are not eligible for coverage under this policy.

Broad, unspecified toxicology panels used for low‑yield indications are discouraged and may be considered unnecessary. For example, routine blanket screening for agents such as acetaminophen or salicylates in certain emergency department psychiatric pre‑administration populations has been judged by cited studies to be unnecessary and wasteful, and such indiscriminate screening is not supported as a covered indication in this policy.

Routine pre‑administration screening for acetaminophen or salicylates in psychiatric settings is not supported by the evidence cited and is regarded as of limited clinical utility. The policy emphasizes targeted, clinically justified testing rather than universal pre‑administration toxicology screens in psychiatric or similar low‑yield contexts.

SAMHSA guidance and referenced regulatory materials note that point‑of‑care immunoassay results alone are insufficient to meet regulatory requirements for opioid treatment program (OTP) drug testing. Definitive, confirmatory testing (e.g., GC‑MS or LC‑MS/MS) is recommended when regulatory compliance is required or when immunoassay results will drive important clinical or programmatic decisions.

Routine additional drug testing or specimen validity testing performed without the required case‑by‑case authorization (for example, HHS rules governing additional testing of oral fluid specimens) is not permitted. Likewise, routine universal urine drug screening (for instance in pregnancy) without documented consent and compliance with state law is discouraged; such tests may be excluded from coverage when they fall outside the policy's clinically indicated scenarios or required authorizations.

When a government policy (for example an applicable Local Coverage Determination, National Coverage Determination, or state Medicaid rule) excludes a service or prescribes different coverage rules, that government policy takes precedence and governs coverage determinations for members subject to that program. Providers should consult the referenced government coverage sources for the controlling rules.

The reference materials cited in this policy do not provide an exhaustive list of explicit test exclusions beyond those noted above but do document limitations of immunoassays, distinctions between clinical and forensic testing, and situations where definitive testing is preferred. Use of these citations is intended to inform appropriate, clinically justified test selection rather than to enumerate additional blanket exclusions.

Specimen validity testing (for example, urine specific gravity, creatinine, pH, oxidant screening, or genetic identity testing) is not covered under this policy. Likewise, same‑day duplicate testing of the same drug or metabolites from two different specimens and multiple presumptive tests per patient per date of service are considered not reasonable/necessary and are not reimbursed.

Covered Indications and Clinical Scenarios

Testing Frequency and Limits

presumptive or definitive drug testing — Varies by risk and treatment phase

ScopePresumptive or definitive drug testing frequency varies by patient risk level and treatment phase; examples in the policy include presumptive low risk 1-2 times/year, moderate risk 2-4 times/year, high risk 4-5 times/year, and definitive testing schedules for substance use disorder patients (e.g., 0–30 days up to 1/week; 31–90 days 1–3/month).

Presumptive monitoring examplesLow risk: up to 1-2 times/year after initiation; Moderate risk: up to 2-4 times/year after initiation; High risk: up to 4-5 times/year after initiation.

Definitive testing examplesFor patients in substance use treatment: 0–30 days abstinence — random definitive testing not to exceed 1/week; 31–90 days — 1–3/month (≤3/month); >90 days — 1–3 every three months (≤3/3 months).

Aberrant behavior testingTesting at time of visit for individuals with aberrant behavior (lost prescriptions, early refill requests, intoxication) meets coverage criteria.

No explicit frequency limits included in this section

Procedure Codes and Coding Rules

Not reimbursed codesmixedNot Covered

Any AMA definitive drug class codes

Any AMA definitive drug class codes are not reimbursed

Presumptive CPT CodesCPT

80305	Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; capable of being read by direct optical observation only (e.g., utilizing immunoassay), includes sample validation when performed, per date of service
80306	Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; read by instrument assisted direct optical observation (e.g., utilizing immunoassay), includes sample validation when performed, per date of service
80307	Drug test(s), presumptive, any number of drug classes, any number of devices or procedures; by instrument chemistry analyzers (e.g., utilizing immunoassay), chromatography, and mass spectrometry either with or without chromatography, includes sample validation when performed, per date of service

Proprietary / U-codesCPT

0007U	Drug test(s), presumptive, with definitive confirmation of positive results, any number of drug classes, urine, includes specimen verification including DNA authentication in comparison to buccal DNA, per date of service (Proprietary test: ToxProtect)
0011U	Prescription drug monitoring, evaluation of drugs present by LC-MS/MS, using oral fluid, reported as a comparison to an estimated steady-state range, per date of service (Proprietary test: Cordant CORE™)
0051U	Prescription drug monitoring, evaluation of drugs present by LC-MS/MS, urine, 31 drug panel, quantitative results, per date of service (Proprietary test: UCompliDx)
0054U	Prescription drug monitoring, 14 or more classes of drugs and substances, definitive tandem mass spectrometry with chromatography, capillary blood, quantitative report with therapeutic and toxic ranges, per date of service (Proprietary test: AssuranceRx Micro Serum)
0079U	Comparative DNA analysis using multiple selected SNPs, urine and buccal DNA, for specimen identity verification (Proprietary test: ToxLok™)
0082U	Drug test(s), definitive, 90 or more drugs or substances, definitive chromatography with mass spectrometry, and presumptive by instrument chemistry analyzer, urine, report of presence or absence with interactions described (Proprietary test: NextGen Precision™ Testing)
0093U	Prescription drug monitoring, evaluation of 65 common drugs by LC-MS/MS, urine, each drug reported detected or not detected (Proprietary test: ComplyRX)
0227U	Drug assay, presumptive, 30 or more drugs or metabolites, urine, LC-MS/MS
0328U	Reaction monitoring (MRM), with drug or metabolite description, includes sample validation (Proprietary test: Comprehensive Screen)

Definitive drug testing G-codesHCPCS

G0480	Drug test(s), definitive, utilizing methods able to identify individual drugs and distinguish structural isomers, with stable isotope/internal standards and method-specific calibration; qualitative or quantitative, 1-7 drug(s); includes specimen validity testing, per day
G0481	Drug test(s), definitive, same method requirements as G0480; qualitative or quantitative, 8-14 drug class(es), includes specimen validity testing, per day
G0482	Drug test(s), definitive, same method requirements as G0480; qualitative or quantitative, 15-21 drug class(es), includes specimen validity testing, per day
G0483	Drug test(s), definitive, performed without method- or drug-specific calibration, matrix-matched QC, or use of stable isotope/internal standards; qualitative or quantitative, any number of drug classes, includes specimen validity testing, per day

Maximum drug class panel for definitive testing — ≤ 7 drug classes

Maximum panel sizeDefinitive (confirmatory) drug testing is limited to a maximum of 7 drug classes for coverage; panels larger than 7 drug classes do not meet coverage criteria.

G-code mappingHCPCS G0480 corresponds to definitive testing for 1–7 drug(s)/classes (other G-codes map to larger class counts).

Request requirementLaboratory-based definitive testing up to seven classes must be specifically requested with documented rationale by the treating physician.

DRI Amphetamines Assay cutoffs — 500 ng/mL (amphetamine), 1000 ng/mL (methamphetamine)

Amphetamine cutoffDRI Amphetamines Assay cutoff: 500 ng/mL for amphetamine.

Provider Actions, Documentation, and Billing Requirements

Documentation Required

OTP admission testing requirement

Opioid treatment programs (OTPs) must perform drug testing prior to admission. At minimum, testing should include opioids, methadone, amphetamines, cocaine, and benzodiazepines; inclusion of other drug classes should be determined by community drug-use patterns or individual medical indications. Benzodiazepines, barbiturates, and alcohol (e.g., ethyl glucuronide) are strongly recommended for inclusion when clinically indicated.

OTPs: test at admission for opioids, methadone, amphetamines, cocaine, benzodiazepines
Consider additional classes based on local patterns or clinical indication
Include benzodiazepines, barbiturates, and alcohol testing when recommended

Prior Authorization

Additional testing requires prior authorization (HHS‑certified oral fluid)

Routine additional drug or specimen validity testing on HHS‑certified oral fluid specimens requires case‑by‑case authorization per HHS rules. An HHS‑certified laboratory is not authorized to routinely perform additional drug and/or specimen validity tests at an MRO's request without prior authorization from the Secretary or designated HHS representative, except for determination of d,l stereoisomers of amphetamine and methamphetamine. Additional testing may be authorized when done for reasonable suspicion or post‑accident on a case‑by‑case basis.

Ordering Requirements and Clinical Decision Support

Note

Services Not Covered / Exclusions

The following services are explicitly not covered: proprietary multi‑analyte proprietary tests (e.g., CareView360 and other U‑code products), specimen validity testing (urine specific gravity, creatinine, pH, oxidant level, genetic identity), definitive panels that exceed 7 drug classes, same‑day duplicate analyte testing from different specimens, and any AMA definitive drug class codes identified as not reimbursed.

Routine, broad toxicology screening performed without a specific clinical indication (for example population‑level or blanket screening) is identified in the literature as low‑value care and is not supported as covered under this policy. Ordering should be limited to targeted, evidence‑based clinical scenarios where results are likely to alter management.

The multicenter retrospective study cited (Farkas et al., 2021) concluded that routine acetaminophen or salicylate screening in emergency department psychiatric pre‑administration was unnecessary; the policy aligns with that evidence by discouraging such indiscriminate testing as a covered service.

Point‑of‑care immunoassay (POC) results alone do not satisfy regulatory requirements for opioid treatment program testing; definitive confirmatory testing is required for regulatory compliance and for situations where definitive identification affects clinical or program decisions.

Additional drug or specimen validity testing on HHS‑certified oral fluid specimens or routine extra testing requested by a medical review officer may require prior authorization from the Secretary or designated HHS representative; such routine additional testing without authorization may not be permitted and may be denied.

If an applicable government policy (LCD/NCD or state Medicaid) excludes a service, that exclusion supersedes this policy for members covered under the government program. Providers should follow the government policy for coverage and reimbursement determinations in those cases.

Definitions and Terms

Drug(s) of abuse (DOA) definition and scope

DOA definitionA drug, chemical, or plant product known to be misused for recreational purposes; may include legitimately prescribed medications misused recreationally.

Common matricesMultiple biological matrices may be tested (urine most commonly used; blood, hair, and saliva also referenced).

Policy scope exclusionsPolicy addresses outpatient clinical toxicology and excludes forensic testing and therapeutic drug monitoring (TDM).

Therapeutic drug monitoring (TDM) — excluded from policy scope

TDM excludedTherapeutic drug monitoring (sampling of plasma or serum drug levels to determine optimal dosing) is excluded from this policy's scope.

ReasonTDM serves dosage optimization rather than detection of misuse and is not addressed by clinical toxicology coverage criteria here.

Background, Evidence, and Guidance

Citations and bibliographic references listed in this policy provide the evidence base and guideline context for the coverage criteria; they do not impose separate prior authorization requirements within this excerpt. Providers should consult the cited references and applicable payer requirements when ordering tests.

Definitive analytic methods (for example, GC‑MS, LC‑MS, LC‑MS/MS) offer greater specificity and sensitivity than immunoassays and are recommended as the preferred confirmatory approach when results will influence major clinical or regulatory decisions. The policy recommends reflexing positive or clinically discordant presumptive immunoassay results to definitive mass spectrometry‑based methods and documents these preferences with supporting guideline citations.

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyPrescription Medication and Illicit Drug Testing in the Outpatient Setting

Policy CodePolicy N/A

Change TypeNo material changes

Effective DateN/A

Next Review DateN/A

Key ActionRequest definitive testing (up to seven drug classes) only when specifically ordered by the treating physician with documented clinical rationale.

SourceLink

On This Page

Oral fluid, hair, and blood/serum/plasma are acceptable in select clinical situations (e.g., anuric patients, dialysis) depending on detection window and clinical question; oral fluid minimum testing for marijuana and cocaine is noted by federal guidance.

Use depends on agent detectability and clinical context

Quantitative testing use: Do not use quantitative definitive urine testing solely to assess adherence to prescribed dosage; reserve quantitative testing for evaluating variant metabolism, complex cases (multiple opioids), suspected sample tampering, or when concentrations inform management.

ASAM and AACC guidance

Some guidelines recommend ≥3/year or more frequent testing

acute psychosis with unclear exposure

Referenced by psychiatric society guidance

Obstetric screening: Screening for substance use should be part of comprehensive obstetric care using validated tools; urine drug testing should be performed in compliance with state law and with patient consent, and confirmatory testing should be requested when appropriate.first prenatal visit or as clinically indicated

ACOG recommends validated screening and cautions about routine urine testing without consent

Policy statementNo single explicit numeric overall frequency limit is mandated across the section; frequency is determined by risk stratification and clinical judgment.

Guideline dependenceDocument references multiple guideline sources and notes that exact numeric presentation varies across document lines.

ImplicationProviders should use risk assessment tools and cited guideline ranges rather than rely on a single frequency cap in this section.

UDM (urine) — Monitoring frequency by risk

Low-risk UDMEvery 6–12 months or at least annually for low-risk patients (baseline then at least annually).

Moderate-risk UDMEvery 3–6 months or at least 2 times per year for moderate-risk patients.

High-risk UDMEvery 1–3 months or at least 3 times per year for high-risk patients; random/unannounced testing preferred for higher-risk levels.

urine drug testing (UDT) — 1-4

Typical annual frequency rangeRecommended urine drug testing (UDT) frequency generally falls between 1 and 4 times per year depending on risk level and guideline source.

Random testing preferenceGuidelines support random (unannounced) testing rather than scheduled testing, especially for monitoring higher-risk patients.

Contextual useUse UDT as part of baseline assessment prior to opioid initiation and for ongoing monitoring as clinically indicated.

UDT for opioid therapy — As clinically indicated

UDT for opioid therapyPerform urine drug testing as part of risk assessment prior to initiating opioid therapy and for ongoing monitoring; frequency determined by patient risk and clinical judgment.

Baseline requirementPerform baseline UDM prior to initiation of opioid therapy in patients considered for opioids.

Method preferenceDefinitive testing (GC-MS/LC-MS/MS) is preferred for baseline assessment and when results will inform major clinical decisions, but immunoassays may be acceptable for low-risk patients or when required by payer/institutional policy.

Not specified in this excerpt

Not specified in excerptNo specific content or threshold provided in the available excerpt for this item.

ImplicationRefer to full policy text or sources for details not included in this excerpt.

ActionDocument clinical indication and consult guideline references when frequency or threshold is unclear.

Methamphetamine cutoffDRI Amphetamines Assay cutoff: 1000 ng/mL for methamphetamine.

Confirmation recommendationManufacturer recommends that positive results by this assay be confirmed by a non-immunological method such as GC/MS.

DRI Cocaine Metabolite Assay cutoff — 150-300 ng/mL

Benzoylecgonine cutoff rangeDRI Cocaine Metabolite Assay concentration cutoff range: 150–300 ng/mL.

Metabolite targetedAssay detects benzoylecgonine, the major urinary metabolite of cocaine.

Detection window noteCocaine itself is rapidly metabolized; benzoylecgonine detection in urine can persist for days depending on use patterns.

THC immunoassay cutoffs discussed — 20 ng/mL (some studies), federal cutoff 50 ng/mL

Reported cutoffs discussedSome studies discuss THC immunoassay cutoffs as low as 20 ng/mL in research contexts; the federal workplace cutoff commonly used is 50 ng/mL.

Assay targetImmunoassays detect delta-9-THC metabolite rather than parent THC; metabolite persistence depends on exposure extent.

False-positive contextLower cutoffs (e.g., 20 ng/mL) can yield positives from heavy second-hand exposure under poor ventilation; federal 50 ng/mL cutoff is less likely to do so.

POC Barbiturate positive detection concentrations — 200-300 ng/mL reported

POC barbiturate detectionPoint-of-care barbiturate immunoassays report positive detection concentrations in the range of approximately 200–300 ng/mL depending on the barbiturate and assay.

Assay limitationsPOC tests like Instant-View® detect unchanged secobarbital and may vary in detection of other barbiturates depending on concentration.

Confirmatory testingPOC positive results should be confirmed with definitive testing as indicated by clinical context and assay limitations.

PCP assay cutoff — 25 ng/mL

PCP assay cutoffCommon qualitative immunoassay cutoff for PCP (CEDIA®) reported at 25 ng/mL.

High reactivityCEDIA® reports 100% reactivity at 25 ng/mL for PCP in manufacturer materials.

Confirmation recommendedPositive immunoassay results should be confirmed by definitive spectrometric methods when clinical decisions depend on the result.

Number of drugs / drug classes — G0480: 1-7; G0481: 8-14; G0482: 15-21; G0483: any number

G0480G0480: Definitive drug test(s) for 1–7 drug(s)/classes (qualitative or quantitative).

G0481G0481: Definitive drug test(s) for 8–14 drug class(es).

G0482/G0483G0482: 15–21 drug classes; G0483: any number of drug classes (performed without method- or drug-specific calibration/standards).

Prior authorization required for routine additional tests on HHS‑certified oral fluid specimens
Exception: determination of d,l stereoisomers of amphetamine/methamphetamine
Additional testing permitted with case‑by‑case approval for reasonable suspicion or post‑accident

Note

Prior authorization not specified in references

The references cited in this section (guidelines, studies, and code listings) do not themselves impose any payer‑specific prior authorization requirements. Where prior authorization is required by payer policy it will be specified separately; consult the member's benefit documents and payer prior authorization resources.

References provide clinical guidance but do not establish payer prior authorization rules
Check payer/member-specific documents for any prior authorization requirements

Billing Rule

Same‑day / duplicate presumptive testing not reimbursed

Same‑day duplicate testing rules: Same‑day testing of the same drug or metabolites from two different specimens (e.g., urine and blood) or multiple presumptive tests on the same date of service is not reimbursed. More than one presumptive test result per patient per date of service is not reimbursed regardless of number of billing providers. Performing both point‑of‑care testing and a reference‑lab presumptive immunoassay on the same specimen is not considered reasonable or necessary.

Not reimbursed: same‑day testing of the same drug/metabolites from two different samples
Not reimbursed: more than one presumptive test result per patient per date of service
Not reimbursed: POC testing plus reference lab presumptive testing on same specimen

Note

Conflict with applicable government policy

If this policy conflicts with an applicable government policy (e.g., LCD/NCD for Medicare or state Medicaid policy), the government policy governs the determination. Providers should consult the Medicare Coverage Database and applicable state Medicaid websites for the most current government rules.

Government policy (LCD/NCD/State Medicaid) takes precedence over this policy in case of conflict
CMS Medicare Coverage Database: https://www.cms.gov/medicarecoverage-database/search.aspx

Note

No explicit denial‑risk statements in references

Some reference excerpts in this section are bibliographic citations and do not state denial risk conditions themselves; they support clinical guidance. They do not constitute standalone payer denial rules.

References used for clinical context and guideline support
No direct denial statements present in bibliographic reference lists

Documentation Required

Medical record must document rationale and medical necessity

Medical record documentation must support the medical necessity for drug testing. Documentation should include pertinent history, relevant physical examination findings, prior test results, and the clinical rationale for testing. Confirmatory/definitive testing requests and results must be supported by documented rationale in the patient's medical record.

Document relevant medical history, physical exam, and prior diagnostic/test results
Support confirmatory/definitive testing requests with documented clinical rationale in the medical record

Documentation Required

Document clinical indication for testing

Document the clinical indication for testing (examples): baseline monitoring prior to initiating opioid therapy, routine monitoring in chronic non‑cancer pain, suspected overdose, altered mental status, psychiatric presentation, pregnancy with high‑risk screening results, newborns with maternal history of substance abuse, or other specific clinical events. The monitoring frequency should be documented and tied to assessed patient risk.

Document indication: baseline assessment prior to opioid initiation, routine monitoring, suspected overdose, altered mental status, psychiatric evaluation
Document indication in pregnancy when screening high‑risk individuals and in newborns when maternal substance use is suspected

Documentation Required

Assay capability and confirmatory testing documentation

When using immunoassays (especially in office/POC settings), clinicians must reference the assay package insert or consult laboratory personnel to document the assay's capabilities and limitations. Documentation should note when immunoassay limitations necessitate definitive testing (e.g., cross‑reactivity, inability to detect specific metabolites or designer drugs).

Reference package insert or consult laboratory personnel to document assay capabilities/limitations
Document rationale for confirmatory testing when immunoassay is insufficient

Documentation Required

Document baseline assessment, risk stratification, and monitoring plan

Document baseline assessment, risk stratification, and an ongoing monitoring plan that specifies UDT frequency based on risk (e.g., at least annually for low‑risk, two or more times per year for moderate‑risk, and three or more times per year for high‑risk patients). Record the chosen specimen type (urine, oral fluid, blood if anuric) and justification.

Document baseline UDT prior to initiating controlled substances
Document risk stratification and monitoring frequency tied to risk level
Document specimen choice and justification (blood acceptable for anuric/dialysis patients; oral fluid when appropriate)

Billing Rule

Procedure code and billing documentation

Claims should include the specific procedure codes appropriate to the test performed. Use presumptive codes 80305–80307 for immunoassay/presumptive testing and definitive/G‑codes (e.g., G0480 for 1–7 drug definitive testing) or specific proprietary/definitive codes where applicable. Proprietary comprehensive definitive assays (e.g., 0328U) and definitive testing codes should be billed consistent with coverage limits (definitive testing limited to ≤7 drug classes unless specifically requested with documented rationale).

Presumptive CPT codes: 80305, 80306, 80307
Definitive/HCPCS: G0480 (definitive 1–7 drug), proprietary codes (e.g., 0328U) as applicable
Definitive testing for >7 drug classes is not covered unless specific documented rationale is provided

Note

No explicit provider documentation or submission requirements in references

This section's reference lists do not state explicit provider submission workflows or additional payer provider documentation beyond medical‑record requirements and code use. Providers should follow standard claim submission rules and any payer‑specific instructions published separately.

Reference lists are bibliographic and do not add extra provider submission requirements
Follow payer's published claim submission and documentation procedures

Documentation Required

Recommend initial presumptive immunoassay with reflex to definitive testing

Initial presumptive testing is recommended using immunoassays (laboratory‑based or POC) with reflex to definitive testing when results are unexpected, unexplained, or clinically inconsistent. Immunoassays provide rapid screening but have known sensitivity/specificity limitations and require confirmatory definitive testing for critical clinical decisions.

Recommend initial presumptive immunoassay/POC screening with reflex to definitive testing when indicated
POC immunoassays are useful for rapid screening but may require confirmatory definitive testing for management decisions

Documentation Required

ASIPP algorithm: baseline POC immunoassay with risk‑based monitoring and confirmatory testing

ASIPP algorithm: perform baseline POC immunoassay at initiation of opioid therapy. If baseline results are appropriate and explained, continue compliance monitoring with random POC immunoassay at 1–3 months and thereafter at 6–12 months if results remain appropriate. If results are inappropriate or unexplained, perform confirmatory definitive testing and repeat UDT at one month or next appointment; document all steps and rationale.

Baseline: POC immunoassay at initiation per ASIPP
If baseline appropriate: random POC immunoassay in 1–3 months, then 6–12 months if continued appropriate
If inappropriate/unexplained: perform confirmatory definitive testing and repeat UDT at ~1 month or next visit

The document excerpts are primarily bibliographic and guideline citations; they do not provide a comprehensive list of not‑covered individual tests beyond the exclusions already stated. The references are included to document assay limitations and to support the policy's coverage logic rather than to list further explicit exclusions.

ActionOrder TDM through appropriate therapeutic drug monitoring policies/protocols, not this toxicology policy.

Presumptive (immunoassay) testing — definition and limitations

DefinitionPresumptive (immunoassay) testing: qualitative or semi-quantitative antibody-based screening with rapid turnaround but lower sensitivity and specificity and susceptibility to cross-reactivity.

Use caseSuitable for initial, rapid assessment (POC or lab-based) and may be used for baseline or routine monitoring, particularly in low-risk patients.

LimitationPositive presumptive results generally require confirmatory definitive testing when discordant with clinical expectations or when results inform major decisions.

Definitive testing — chromatography plus mass spectrometry definition

DefinitionDefinitive testing: chromatographic plus mass spectrometric methods (e.g., GC-MS, LC-MS/MS) that provide higher specificity and sensitivity and identify specific drugs/metabolites.

Preferred useRecommended for baseline assessment, confirmation of unexpected or clinically consequential results, and whenever results will inform major clinical or nonclinical decisions.

Method examplesGC-MS, LC-MS, LC-MS/MS are cited as standard definitive techniques.

Definitive testing analytic methods (GC-MS, LC-MS/MS) described

Analytic methodsDefinitive testing analytic methods include gas chromatography-mass spectrometry (GC-MS) and liquid chromatography-tandem mass spectrometry (LC-MS/MS).

RationaleThese methods allow identification of specific drugs and distinction of structural isomers with higher accuracy than immunoassays.

Clinical recommendationUse MS-based definitive methods for baseline and when accuracy is required for management decisions.

Immunoassay/POC testing — definition and limitations

Definition and roleImmunoassay/POC testing: qualitative presumptive tests (lab-based or point-of-care) that detect drug classes but have limitations in sensitivity, specificity, and cross-reactivity.

Operational notePOC immunoassays can provide immediate results but require package-insert review or lab consultation to interpret limitations and cross-reactivity risks.

ConfirmationPOC positives often need definitive confirmation when results are clinically consequential.

Presumptive immunoassay (POC or lab-based) — definition and package-insert review requirement

Presumptive immunoassay definitionPresumptive immunoassay (POC or lab-based): qualitative screening tests that detect drug classes but have limitations in specificity and sensitivity and require review of package insert or lab consultation.

Documentation requirementPhysicians using POC testing must reference the POC package insert and/or consult laboratory personnel to determine assay capabilities and limitations.

Appropriate useMay be used as initial screening or routine monitoring when definitive testing is not required or available.

Definitive testing — confirmatory techniques recommended when indicated

Confirmatory recommendationDefinitive/confirmatory testing is recommended when presumptive immunoassay results are inconsistent with clinical expectations or when results will affect major clinical/legal decisions.

When indicatedUse confirmatory techniques to identify specific substances not captured by immunoassays, quantify levels when needed, and resolve discordant results.

Method examplesGC/MS and LC-MS/MS are cited as appropriate confirmatory techniques.

Adulterated specimen — definition

DefinitionAdulterated specimen: a specimen altered as evidenced by substances not normally present or abnormal concentrations of normal constituents (e.g., nitrite in urine).

ConsequenceAdulterated specimens may prompt additional testing or rejection per HHS guidance.

Policy noteHHS rules govern additional validity testing on oral fluid specimens and case-by-case authorization for extra testing.

Oral fluid minimum panel (HHS) — marijuana and cocaine required

Oral fluid minimum panelHHS requires that each oral fluid specimen be tested at minimum for marijuana and cocaine as part of the federal oral fluid testing panel.

Additional analytesFederal guidance authorizes testing for other Schedule I/II drugs and biomarkers per the oral fluid testing panel and MRO request.

Authorization limitsAn HHS-certified lab may not routinely perform additional testing at MRO request without prior authorization from the Secretary or designated HHS representative (with limited exceptions).

LDT — Laboratory-developed test definition and CLIA context

LDT definitionLaboratory-developed test (LDT): a test developed and validated in-house by a laboratory; regulated by CMS as high-complexity under CLIA '88 and not FDA-cleared/approved for clinical use.

Regulatory implicationLDTs are commonly used clinically but must meet CLIA high-complexity requirements.

Coverage notePolicy references LDT use but does not substitute CLIA/CAP/federal requirements for laboratory operations.

Immunoassay-based urine drug test — definition and limitations referenced

DefinitionImmunoassay-based urine drug test: a screening laboratory method using antibodies to detect drug classes; noted to have limitations in sensitivity and potential interferences.

Operational guidanceClinicians must be aware of potential false-positives/negatives and consult package inserts or laboratory personnel for interpretation.

Confirmation requirementPositive immunoassay results that are inconsistent with clinical findings should be confirmed by definitive MS-based methods.

Urine drug testing is the most common outpatient testing modality due to longer detection windows, ease of collection, and relative cost‑effectiveness; however, coverage and reimbursement limits apply based on specimen type and testing purpose. The policy specifies that only urine or oral fluid specimens are covered except in circumstances such as anuric chronic renal failure where blood testing may be appropriate.